FDA Drug Recalls
676 recalls · Class II, newest first
Class II · Moderate risk Ongoing Mar 5, 2025
Reason cGMP Deviations: The recall was initiated due to detected trace levels of benzene in a specific lot of this product lot (MYX46W), however out of an…
Class II · Moderate risk Ongoing Mar 5, 2025
Reason Chemical Contamination: This recall has been initiated due to detected trace levels of benzene.
Class II · Moderate risk Ongoing Mar 5, 2025
Reason Presence of foreign substance: Presence of Benzene.
Class II · Moderate risk Ongoing Mar 5, 2025
Reason Presence of foreign substance: Presence of Benzene.
Class II · Moderate risk Ongoing Mar 5, 2025
Reason Failed Dissolution Specifications
Class II · Moderate risk Ongoing Mar 5, 2025
Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit.
Class II · Moderate risk Ongoing Mar 4, 2025
Reason CGMP Deviations: Nitrosamine Drug Substance Related Issue impurity above the daily acceptable intake limit defined by the Food and Drug…
Class II · Moderate risk Ongoing Feb 28, 2025
Reason CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit
Class II · Moderate risk Ongoing Feb 28, 2025
Reason CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit
Class II · Moderate risk Ongoing Feb 28, 2025
Reason CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit
Class II · Moderate risk Ongoing Feb 28, 2025
Reason CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit
Class II · Moderate risk Ongoing Feb 28, 2025
Reason Chemical Contamination: Presence of benzene
Class II · Moderate risk Ongoing Feb 28, 2025
Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
Class II · Moderate risk Ongoing Feb 28, 2025
Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
Class II · Moderate risk Ongoing Feb 28, 2025
Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
Class II · Moderate risk Ongoing Feb 27, 2025
Reason Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.
Class II · Moderate risk Ongoing Feb 27, 2025
Reason Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.
Class II · Moderate risk Ongoing Feb 25, 2025
Reason Presence of Foreign Tablets/Capsules.
Class II · Moderate risk Ongoing Feb 25, 2025
Reason Failed Dissolution Specifications - low dissolution results
Class II · Moderate risk Ongoing Feb 24, 2025
Reason Chemical Contamination: Presence of benzene.
Class II · Moderate risk Completed Feb 18, 2025
Reason Lack of Assurance of Sterility: due to a quality control process deviation
Class II · Moderate risk Ongoing Feb 17, 2025
Reason Subpotent Drug
Class II · Moderate risk Ongoing Feb 17, 2025
Reason Subpotent Drug
Class II · Moderate risk Ongoing Feb 17, 2025
Reason Defective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.
Class II · Moderate risk Ongoing Feb 17, 2025
Reason Defective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.